Ligand Pharmaceuticals Incorporated (LGND)
| Previous Close | 70.37 |
| Open | 70.59 |
| Bid | 70.63 x 100 |
| Ask | 71.30 x 200 |
| Day's Range | 70.59 - 70.97 |
| 52 Week Range | 49.24 - 94.57 |
| Volume | |
| Avg. Volume | 174,588 |
| Market Cap | 1.257B |
| Beta (5Y Monthly) | 0.92 |
| PE Ratio (TTM) | 23.42 |
| EPS (TTM) | 3.03 |
| Earnings Date | May 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jul 02, 2010 |
| 1y Target Est | 116.80 |
Business WireLigand to Report First Quarter 2024 Financial Results on May 7, 2024
JUPITER, Fla., April 23, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, May 7, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update.
ZacksWall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in Ligand (LGND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ZacksAptevo (APVO) Stock Plummets 79% in a Week: Here's Why
Aptevo (APVO) plunges after it issues secondary shares, which are not only issued at a significant discount but also substantially dilute the existing shareholder base.
